2018 Press Releases

Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome

READ MORE

Ovid Therapeutics Announces OV935/TAK-935 Presentations at the American Epilepsy Society 72nd Annual Meeting

READ MORE

Ovid Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27

READ MORE

Ovid Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Recent Clinical Progress

READ MORE

Ovid Therapeutics Presents Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101 for the Treatment of Angelman Syndrome at the 65th AACAP Annual Meeting

READ MORE

Ovid Therapeutics Receives “Company Making a Difference Award” from CDKL5 Deficiency Disorder Community

READ MORE

Ovid Therapeutics to Host Conference Call and Webcast on Thursday, October 25, at 10:30 a.m. EDT

READ MORE

Ovid Therapeutics Announces Initiation of Two Phase 2 Clinical Trials of OV935/TAK-935 for Pediatric Patients with Rare Epilepsies

READ MORE

Ovid Therapeutics to Present at Two Investor Healthcare Conferences in October 2018

READ MORE

Dr. Yaron Werber, Chief Business and Financial Officer, to Return to Wall Street

READ MORE

Ovid Therapeutics to Present at Two Investor Healthcare Conferences in September 2018

READ MORE

Ovid Therapeutics Announces Phase 2 STARS Topline Data Accepted for Presentation at American Academy of Child And Adolescent Psychiatry Annual Meeting

READ MORE

Ovid Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Recent Clinical Progress

READ MORE

Ovid Therapeutics Announces Positive Topline Data from Phase 2 STARS Trial of OV101 for the Treatment of Angelman Syndrome

READ MORE

Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with Three New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)

READ MORE

Ovid Therapeutics Announces Presentations Related to OV101 Fragile X Syndrome Program at the 16th National Fragile X Foundation (NFXF) International Conference

READ MORE

Ovid Therapeutics Announces Initiation of Phase 2 ROCKET Clinical Trial to Evaluate OV101 in Fragile X Syndrome

READ MORE

Ovid Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference on June 8, 2018

READ MORE

Ovid Therapeutics Announces Two Oral Presentations at the 14th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV)

READ MORE

Ovid Therapeutics Reports First Quarter 2018 Financial Results and Corporate Progress

READ MORE

Ovid Therapeutics to Present at Deutsche Bank’s 43rd Annual Health Care Conference on May 9, 2018

READ MORE

Ovid Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Progress

READ MORE

Ovid Therapeutics to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Thursday, March 29, 2018

READ MORE

Ovid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Fragile X Syndrome

READ MORE

Ovid Therapeutics to Present at Two Upcoming Investor Conferences

READ MORE

Ovid Therapeutics Announces Multiple Poster Presentations of OV101 and TAK-935/OV935 at the American Academy of Neurology 70th Annual Meeting

READ MORE

Ovid Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference

READ MORE